Cochrane · systematic review · CD008989
Long‐acting beta₂‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta₂‐agonist alone for chronic obstructive pulmonary disease
Farne, HA, Cates, CJ · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 33.3%Moderate 6 · 50%High 2 · 16.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsLong‐acting beta2‐agonist plus tiotropium versus tiotropium alone
Population: addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in quality of life Long‐acting beta2‐agonist plus tiotropium vs tiotropium alone | no estimate extracted | 5 studies · 6709 participants | Moderate |
Quality of life SGRQ responder analysis at 6 months Long‐acting beta2‐agonist plus tiotropium vs tiotropium alone | OR 1.32 [1.19, 1.46] | 3 studies · 5978 participants | Moderate |
Hospital admission (all cause) Long‐acting beta2‐agonist plus tiotropium vs tiotropium alone | OR 1.01 [0.86, 1.19] | 4 studies · 4856 participants | Moderate |
Hospital admission (exacerbation) Long‐acting beta2‐agonist plus tiotropium vs tiotropium alone | OR 1.02 [0.8, 1.28] | 4 studies · 4856 participants | Low |
Mortality (all cause) Long‐acting beta2‐agonist plus tiotropium vs tiotropium alone | OR 1.24 [0.81, 1.9] | 8 studies · 9633 participants | Low |
Change in trough FEV1 (L) Long‐acting beta2‐agonist plus tiotropium vs tiotropium alone | no estimate extracted | 10 studies · 9573 participants | High |
Long‐acting beta2‐agonist plus tiotropium versus long‐acting beta2‐agonist alone
Population: addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in quality of life Long‐acting beta2‐agonist plus tiotropium vs long‐acting beta2‐agonist alone | no estimate extracted | 4 studies · 3378 participants | Moderate |
Quality of life SGRQ responder analysis at 6 months Long‐acting beta2‐agonist plus tiotropium vs long‐acting beta2‐agonist alone | OR 1.53 [1.31, 1.79] | 2 studies · 2923 participants | Moderate |
Hospital admission (all cause) Long‐acting beta2‐agonist plus tiotropium vs long‐acting beta2‐agonist alone | OR 0.93 [0.76, 1.14] | 3 studies · 3514 participants | Moderate |
Hospital admission (exacerbation) Long‐acting beta2‐agonist plus tiotropium vs long‐acting beta2‐agonist alone | OR 0.9 [0.66, 1.22] | 3 studies · 3514 participants | Low |
Mortality (all cause) Long‐acting beta2‐agonist plus tiotropium vs long‐acting beta2‐agonist alone | OR 1.15 [0.62, 2.13] | 3 studies · 3514 participants | Low |
Change in trough FEV1 (L) Long‐acting beta2‐agonist plus tiotropium vs long‐acting beta2‐agonist alone | no estimate extracted | 4 studies · 3513 participants | High |